Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot Study

Korábbi kezelés

• Expected to receive radiotherapy within the next 4 cycles
• Had participated in any other clinical trial within the prior 3 months
• Had received acupuncture treatment within 6 weeks
• Has fever (>38°C) or clinically significant infection within 1 week prior to enrolment
• With a bleeding tendency, and receiving thrombolytics or anticoagulants

Más betegség

• With a combination of serious primary diseases of the heart, cerebrovascular, hepatic, renal, and hematopoietic systems
• With dementia, neurological disorders, mental retardation, or language impairment, and pregnant or breastfeeding women
• Combined autoimmune diseases, hematologic disorders, or long-term use of hormones or immunosuppressive drugs
• Has known history of Human Immunodeficiency Virus (HIV) or solid organ transplantation
• Has known active Hepatitis B
• Has interstitial lung disease or a history of pneumonitis that required oral of IV glucocorticoids to assist with management
• Has active tuberculosis or indications of severe or uncontrolled systemic diseases

Egyéb

• Unable to complete baseline assessments
• Combined with a primary tumor from other sites
• With legal incapacity
• With skin breakdown at the acupuncture point that interferes with treatment
• With a pacemaker
• With a fear of acupuncture

• Has a histologically-confirmed or cytologically confirmed diagnosis of stage IIIB or IV NSCLC.
• PD-L1 TPS<50%
• EGFR/ALK wild-type
• Has not received prior systemic treatment for advanced NSCLC. For patients who received preoperative neoadjuvant chemotherapy or postoperative adjuvant chemotherapy or radical chemoradiotherapy, if the disease progresses occurred one six months after the last treatment, they can be enrolled. Patients who received targeted therapy or immunotherapy can not be enrolled.
• Has a performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) Performance Status.
• Age≥18 years
• Has a life expectancy of at least 3 months
• Has measurable disease
• Has adequate organ function
• Voluntarily enrolled into the study, sign the informed consent form and have good compliance